E. Paliczka-Cieslik

发表

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma

B. Jarzab, M. Jarzab, D. Handkiewicz-Junak, 2019, Nuclear Medicine and Molecular Imaging.

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi

E. Gubała, B. Jarzab, M. Jarzab, 2010, Thyroid research.

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

B. Jarzab, D. Handkiewicz-Junak, A. Kukulska, 2009, Thyroid research.

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

E. Chmielik, B. Jarzab, D. Handkiewicz-Junak, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer

B. Jarzab, D. Handkiewicz-Junak, Agnieszka Kotecka-Blicharz, 2021, Annals of Nuclear Medicine.

Managing tyrosine kinase inhibitors side effects in thyroid cancer

B. Jarzab, J. Krajewska, E. Paliczka-Cieslik, 2017, Expert review of endocrinology & metabolism.

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes

B. Jarzab, D. Handkiewicz-Junak, J. Krajewska, 2020, Archives of medical science : AMS.

The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma

B. Jarzab, J. Wydmański, J. Krajewska, 2019, Endocrine connections.

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

E. Chmielik, B. Jarzab, D. Handkiewicz-Junak, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.

E. Gubała, B. Jarzab, D. Handkiewicz-Junak, 2016, Endokrynologia Polska.

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma

Dagmara Rusinek, A. Pfeifer, B. Jarzab, 2020, Cancers.

Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy--a prospective study.

B. Jarzab, J. Krajewska, B. Jurecka-Lubieniecka, 2014, Endokrynologia Polska.

[Diagnosis and treatment of thyroid cancer - Polish guidelines].

W. Olszewski, M. Krzakowski, E. Chmielik, 2010, Endokrynologia Polska.

Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update.

Andrzej Cichocki, Agnieszka Kotecka-Blicharz, Marek Niedziela, 2018, Endokrynologia Polska.

[131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].

B. Jarzab, D. Handkiewicz-Junak, J. Krajewska, 2008, Endokrynologia Polska.

Adjuvant radioiodine (RAI) treatment reduces the risk of relapse in low advanced differentiated thyroid carcinoma (DTC)

B. Jarzab, D. Handkiewicz-Junak, J. Krajewska, 2015 .

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer

A. Grządziel, B. Jarzab, J. Krajewska, 2021, BMC Endocrine Disorders.

Carcinoid syndrome with angioedema and urticaria.

B. Filipowska, J. Krajewska, J. Jarząb, 2008, Archives of dermatology.